SAN DIEGO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the following investor conferences in September:
Rodman & Renshaw 17th Annual Global Investment Conference
Wednesday, September 9 from 10:50 to 11:15 AM EDT at the St. Regis Hotel in New York, NY
To access a live webcast of the presentation, please visit the "Events and Presentation" section within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
Wells Fargo 10th Annual Healthcare Conference
Thursday, September 10 from 8:15 to 9:00 AM EDT at the Hyatt Regency in Boston, MA
TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON's pipeline currently includes two clinical-stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
CONTACT: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 firstname.lastname@example.org
Source:TRACON Pharmaceuticals, Inc.